Literature DB >> 26478520

Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae.

Hosam M Zowawi1,2,3,4, Brian M Forde2,5, Mubarak Alfaresi6, Abdulqadir Alzarouni7, Yasser Farahat7, Teik-Min Chong8, Wai-Fong Yin8, Kok-Gan Chan8, Jian Li9, Mark A Schembri2,5, Scott A Beatson2,5, David L Paterson1,2.   

Abstract

Carbapenem resistant Enterobacteriaceae (CRE) pose an urgent risk to global human health. CRE that are non-susceptible to all commercially available antibiotics threaten to return us to the pre-antibiotic era. Using Single Molecule Real Time (SMRT) sequencing we determined the complete genome of a pandrug-resistant Klebsiella pneumoniae isolate, representing the first complete genome sequence of CRE resistant to all commercially available antibiotics. The precise location of acquired antibiotic resistance elements, including mobile elements carrying genes for the OXA-181 carbapenemase, were defined. Intriguingly, we identified three chromosomal copies of an ISEcp1-bla(OXA-181) mobile element, one of which has disrupted the mgrB regulatory gene, accounting for resistance to colistin. Our findings provide the first description of pandrug-resistant CRE at the genomic level, and reveal the critical role of mobile resistance elements in accelerating the emergence of resistance to other last resort antibiotics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26478520      PMCID: PMC4609946          DOI: 10.1038/srep15082

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


The “golden era” when modern medicine saved lives through antibiotic treatment is under serious threat1. In 2013, the Centers for Disease Control and Prevention (CDC) released a landmark report on “Antibiotic Resistance Threats2”. Three microorganisms were tagged as posing a threat level of urgent – Clostridium difficile, carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria gonorrhoeae2. CRE, which include organisms such as Klebsiella pneumoniae and Escherichia coli, are resistant to almost all currently available antibiotics. Almost 50% of patients who develop bloodstream infections with these organisms die from the infection2. In healthcare settings, carbapenem resistant Enterobacteriaceae have increased sharply over the past decade3. Carbapenem resistance is typically mediated by the production of beta-lactamases4, and patients with CRE infections are treated with last-resort antibiotics such as colistin5. The CDC and the European Centre for Disease Prevention and Control (ECDC) have jointly developed definitions for multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria6. Pandrug-resistance implies non-susceptibility to all commercially available antibiotics relevant to the treatment of a particular bacterial infection. Although there has been an anecdotal report of probable pandrug-resistance in K. pneumoniae7, no such isolates have been comprehensively analyzed. In this manuscript, we describe the genetic basis of pandrug-resistance in a K. pneumoniae isolate using single molecule real-time (SMRT) sequencing. We show that a genetic element conferring resistance to carbapenem antibiotics has been acquired and mobilized, leading to insertional inactivation of a gene that results in resistance to colistin. Overall, our analysis provides a comprehensive description of a pandrug-resistant K. pneumoniae isolate at the whole genome level.

Results

Case Record

An 87 year old man, hospitalized in the United Arab Emirates in April 2014, was found to be colonized with multidrug-resistant Klebsiella pneumoniae. The isolate grew from urine and a pre-sacral pressure area but blood cultures were sterile. Susceptibility testing by way of a commercial semi-automated method (Vitek, bioMérieux) showed resistance to all antibiotics tested. The urinary isolate (strain MS6671) was therefore sent to a reference laboratory for further testing. Other K. pneumoniae isolates with this antibiotic resistance phenotype were not detected at the index patient’s hospital.

Pandrug-resistant phenotype of K. pneumoniae MS6671

MS6671 was found to be non-susceptible to all antibiotics tested, which includes cephalosporins, penicillins, carbapenems, aztreonam, aminoglycosides, ciprofloxacin, colistin, tetracyclines, tigecycline, chloramphenicol, trimethoprim-sulfamethoxazole and fosfomycin (Table 1). Thus, the isolate can truly be described as pandrug-resistant6.
Table 1

Antibiotic resistance in K. pneumoniae MS6671.

Antimicrobial CategoryAntimicrobial AgentMIC(mg/L)EUCASTInterpretationGenes previouslyassociated with resistance
AminoglycosidesGentamicin>256RrmtF, aac(6’)-lb-cr
Tobramycin>256R
Amikacin>256R
Netilmicin>256R
AntiMRSA CephalosporinsCeftaroline>32RblaOXA-181,blaCTX-M-15
Antipseudomonal Penicillins andBeta-lactamase InhibitorsTicarcillin/Clavulanate>256RblaOXA-181
Piperacillin/Tazobactam>256R
CarbapenemsErtapenem>32RblaOXA-181, ompK36 (ins aa135–136DT)
Imipenem4NS
Meropenem8R
Doripenem4R
Non-extended Spectrum CephalosporinsCefazolin*>32RblaCTX-M-15
Cefuroxime>256R
Extended Spectrum CephalosporinsCeftriaxone, Cefotaxime>32RblaCTX-M-15
Ceftazidime32R
Cefepime32R
CephamycinsCefoxitin*128RblaOXA-181
Cefotetan*32NS
FluoroquinolonesCiprofloxacin>32RgyrA (Ser83Ile), parC (Ser80Ile), qnrB ompK35 inactivation
Folate-pathway InhibitorsTrimethoprim/Sulfamethoxazole8RdfrA12, dfrA14
GlycylcyclinesTigecycline4RacrAB#
MonobactamsAztreonam32RblaOXA-181, blaCTX-M-15
PenicillinsAmpicillin>256RblaSHV-36
Penicillins and Beta-lactamase InhibitorsAmoxycillin/Clavulanate>256RblaOXA-181
Ampicillin/Sulbactam>256R
PhenicolsChlorampenicol128RcatB1, ompK35 inactivation,
Phosphonic acidsFosfomycin64RfosA,
PolymyxinsColistin128RmgrB inactivation
TetracyclinesTetracycline*32RacrAB3, ompK35 inactivation, tetC
Doxycycline*32R
Minocycline*32R

*Based on the breakpoints of CLSI criteria; Polymyxin B MIC was 32 mg/L.

†Several additional intrinsic factors, such as efflux pumps and porins, which may be involved in multi-drug resistance are also encoded in the genome (Supplementary Table S2).

‡Resistance to trimethoprim. No sul genes identified.

#Tigecycline resistance has been associated with upregulation of acrAB, often resulting from the aberrant expression of ramA and/or ramR. A description of the potential mechanism of tigecycline resistance in MS6671 is provided in the Supplementary Results.

K. pneumoniae MS6671 general genome features

The complete genome of K. pneumoniae MS6671 consists of a circular chromosome 5,402,900 base-pairs in length with an average G-C content of 57%, five circular plasmids and a linear plasmid prophage (Supplementary Table S1). The sequence type of the isolate was ST147. The chromosome of MS6671 is highly similar to K. pneumoniae NTUH-k20448; a hypervirulent strain associated with liver abscess and meningitis, with most variation attributable to differences in their mobile genetic element (MGE) content (Supplementary Figure 1). Further details of the complete genome are provided in the Supplementary Results.

Genetic determinants of pandrug-resistance

In order to determine the genetic basis of pandrug-resistance, we interrogated the genome to identify acquired and intrinsic resistance genes. The majority of acquired antibiotic resistance genes were located on the chromosome, with most beta-lactamase and aminoglycoside resistance genes carried within two copies of a class 1 integron or as part of mobile elements that incorporate the ISEcp1 insertion sequence (Table 1, Supplementary Table S2 and Supplementary Results). Mutations in gyrA and parC that have previously been linked with fluoroquinolone resistance (GyrA Ser83Ile and ParC Ser80Ile) were identified910. Fosfomycin resistance was mediated by a chromosomally encoded copy of fosA11. Mutations in chromosomal genes encoding major outer membrane porins (OmpK35 and OmpK36) were also identified. A novel variant of the ompK36 gene was encoded on the chromosome. The amino acid sequence change is located in loop 3 (L3) of the porin, which constitutes the porin channel eyelet12. L3 mutations have previously been associated with increased resistance to carbapenems131415. Additionally, ompK35 has been disrupted by IS insertion. Inactivation of ompK35 has been associated with increased resistance to a number of different classes of antibiotics, including quinolones and cephalosporins1617. Genes encoding three beta-lactamases, including an extended-spectrum beta-lactamase (ESBL) and a carbapenemase, were detected at different genomic locations – blaSHV-36, blaCTX-M-15, blaOXA-181.

Insertional inactivation of mgrB by a carbapenem-resistance element and colistin resistance

OXA-181 is an oxacillinase capable of hydrolysing carbapenems18. Three copies of an ISEcp1-blaOXA-181 transposon were identified throughout the chromosome (Fig. 1). One of these insertions has resulted in the inactivation of the mgrB gene, a negative regulator of phoPQ. Insertions in mgrB have previously been shown to cause colistin resistance in K. pneumoniae clinical isolates192021. Examination of the DNA flanking the ISEcp1-blaOXA-181 transposons shows that the primary insertion site is within MS6671_10430, followed by intra-chromosomal transposition of ISEcp1-blaOXA-181 and a 37 bp fragment of MS6671_10430 to two other locations in the genome (Fig. 2). The three transposons are bracketed by imperfect 14 bp inverted repeats and flanking 5 bp direct repeats (TATCT, TGAAA and TATAA), providing direct evidence for their transposition activity (Supplementary Table S3).
Figure 1

Diagram of the pandrug-resistant K. pneumoniae MS6671 chromosome highlighting the position and context of mobile genetic elements that harbor antimicrobial resistance genes.

The chromosome of MS6671 is represented to scale by the black bar with ISEcp1 and integron insertion points indicated with red rectangles. Pop-outs display schematic representations of the four ISEcp1 elements which harbor beta-lactamase genes (three copies of blaOXA-181 and one copy of blaCTX-M-15) and a class 1 integron located on the chromosome of MS6671. Insertion elements are highlighted in yellow. The coordinates of each element are indicated above and below the genome bar.

Figure 2

Comparison of ISEcp1-blaOXA-181 transposons from MS6671.

Pairwise nucleotide comparison of ISEcp1-blaOXA-181 (OXA-181) transposons and flanking genomic regions from K. pneumonaie MS6671. ISEcp1 elements are represented by blue rectangles. Protein-coding genes are represented by coloured arrows: blaOXA-181 (green); MS6671_10430 encoding a hypothetical protein (red); other (brown). Left and right flanking inverted repeats (IRL, IRR, IRRalt1, IRRalt2) are represented by yellow bars and 5 bp direct repeat sequences created by duplication of the target sequence during transposition are given (TGAAA, TATCT or TATAA). In the primary insertion site, a single 2,855 bp transposon carrying blaOXA-181 has inserted at TGAAA (position 1152428..1155282) within MS6671_10430. This transposon, similar to Tn2013 previously described in K. pneumoniae Kp331, is flanked by 14-bp inverted repeat sequences, namely IRL and IRRalt1. IRRalt2 lies 23 bp downstream of IRRalt1 within the MS6671_10430 sequence. Mobilisation of the ISEcp1-blaOXA-181 transposon using IRRalt2 instead of IRRalt1 has resulted in a 37 bp fragment of MS6671_10430 (indicated by a small red rectangle) being packaged at the 3’ end of the other two ISEcp1-blaOXA-181 transposons inserted at TATCT and TATAA (position 126108..128999 and position 3345804..3348695, respectively). Grey shading indicates regions of homology (100% nucleotide sequence identity) between sequences.

In a similar fashion, a single copy of ISEcp1-blaCTX-M-15 has inserted into ompK35, leading to inactivation this gene (Fig. 1). The ISEcp1-mediated mobilisation and transposition of blaCTX-M-15, blaOXA-181 and other clinical relevant beta-lactamase resistance genes, including blaCMY and blaACC, has been reported previously2223242526.

K. pneumoniae MS6671 contains two copies of a class 1 integron

A class 1 integron was identified on the chromosome encoding multiple antibiotic resistance genes (arr-3, aac(6′)-Ib-cr, rmtF, catB1) (Fig. 1). These genes result in resistance to rifampin, all aminoglycosides and chloramphenicol. A near-identical copy of this integron was also found on one of the six plasmids (Supplementary Figure S2).

Discussion

This is the first genomic analysis of a pandrug-resistant CRE isolate, as defined by the rigorous CDC/ECDC assessment criteria6. With the advantage of long-reads provided by SMRT sequencing we were able to identify the genomic context of multiple resistance elements. In contrast to short-read technologies, SMRT sequencing allows complex resistance elements to be properly characterized27. This technology platform was used to investigate the German E. coli O104:H11 outbreak28 and more recently to identify plasmid-borne resistance in a large-scale study of CRE following an outbreak at the National Institute for Health Clinical Center2930. Critically, elucidation of the complete K. pneumoniae MS6671 genome using long-read sequencing enabled the context of multiple, identical carbapenem resistance elements to be determined. Based on this analysis we propose a model for the development of pandrug-resistance in this K. pneumoniae isolate, whereby mobile resistance determinants are responsible for driving additional resistance. In this example, ISEcp1 carrying the blaOXA-181 carbapenem resistance gene has inserted three times in the chromosome, with one event causing colistin resistance by insertional inactivation of mgrB. ISEcp1-like insertion sequences are the most common genetic element associated with blaCTX-M, blaCMY and blaACC genes and have more recently been associated with blaOXA-181222324252631. By recognizing a variety of DNA sequences as right inverted repeats (IRR), ISEcp1s are capable of mobilising adjacent genes and inserting at new location3233. Similar to previous reports on the hydrolytic activities of OXA-181183435, elevated MICs for ertapenem, imipenem, meropenem and doripenem were observed for MS6671, indicating hydrolytic activity of OXA-181 towards these carbapenems and a possible blaOXA-181 copy number effect (Table 1). Notably, doripenem resistance was higher than previously reported18. The ompK36 variant encoded by MS6671 has previously been associated with increased resistance to doripenem and doripenem-colistin13, and may contribute to the elevated MIC for doripenem observed in MS6671. Porin deficient E. coli expressing OXA-48-like beta-lactamases have also been shown to have elevated MICs towards carbapenems18. Inactivation of mgrB has recently been associated with resistance to colistin, and appears to be the most common mechanism for polymyxin resistance in K. pneumoniae1920. Specifically, disruption of mgrB results in over expression of the phoPQ signaling system and of the pmrHFIJKLM operon which controls modification of LPS, the target of polymyxin antibiotics36. Insertional inactivation of mgrB with IS5-like or IS1 elements has been previously reported2137, however, the present study is the first to show colistin resistance caused by insertion of a carbapenem resistance element itself. While we cannot rule out the possibility that this mechanism may have occurred in other colistin-resistant K. pneumoniae carrying ISEcp1-blaOXA-18138, the generation of a complete genome sequence of MS6671 provides unequivocal evidence for this novel insertion event. We also found a fourth ISEcp1 element encoding an ESBL (CTX-M-15), which was inserted within the outer membrane porin gene ompK35. Disruption of ompK35 reduces the permeability of the outer membrane and mutants lacking this porin have increased resistance to quinolones, tetracyclines, beta-lactams and chloramphenicol39. Pan-aminoglycoside resistance was mediated by the rRNA methyltransferase RmtF, which was encoded on both chromosomal and plasmid copies of a class 1 integron. We did not have access to investigational antibiotics, such as plazomicin, eravacycline, ceftazidime/avibactam or ceftolozane/tazobactam, to assess their potency against MS6671. MS6671 was defined by multi-locus sequence typing (MLST) as being ST147. K. pneumoniae ST147 was first described in Hungary in 200840. Subsequently, it has been frequently associated with carbapenem resistance, with ST147 producing KPC well described in Greece and Italy4142. For example, epidemics of VIM-producing carbapenem resistant K. pneumoniae ST14743, and KPC-2-producing carbapenem resistant K. pneumoniae4445 have been reported in Greece. Notably, ST147 isolates carrying both blaVIM and blaKPC-2 genes were identified4146. Carbapenem resistant ST147 carrying the blaNDM-1 gene have been isolated in Iraq, Switzerland, Canada and the United Kingdom474849. In MS6671, carbapenem resistance was most likely mediated by the beta-lactamase OXA-181, possibly in combination with permeability defects as has been reported previously in other strains1831. ST147 K. pneumoniae producing OXA-181 have been previously reported from the Indian sub-continent183150. Clearly, in addition to the KPC-producing, carbapenem-resistant K. pneumoniae ST258 clone51, ST147 also represents a clone of K. pneumoniae with a potential for global significance. Fortunately, in six months there have been no further isolates with this resistance phenotype at the index patient’s hospital. However, the occurrence of this strain in the Arabian Gulf is of great significance. OXA-48-like-producing K. pneumoniae are frequent in this region52. It is unknown if this strain originated in the index patient, in another patient at the same hospital or was imported from another hospital, perhaps in another country. There are a large number of expatriates in the Gulf region, and travel to the Indian sub-continent, Europe and the United States is frequent53. The potential for international transfer of multidrug-resistant bacteria5455 emphasizes the need for global surveillance efforts as one part of a strategy to control antibiotic resistance3. In summary, we have provided the first report of a pandrug-resistant isolate of CRE using high-resolution genome data. The CDC has denoted CRE as an urgent threat. The emergence of this highly resistant strain, in a clone that has proven capable of causing outbreaks, raises this threat level even higher.

Methods

Antibiotic Resistance Phenotypic Testing

The K. pneumoniae isolate (hereafter referred to as MS6671) was sent to a reference laboratory (University of Queensland, Centre for Clinical Research) where confirmatory susceptibility testing was performed in order to determine the minimal inhibitory concentrations of all antibiotics used by the Centers for Disease Control and Prevention (CDC) and European Centre for Disease Prevention and Control (ECDC) in defining a pandrug-resistant isolate6. Susceptibility of most tested antibiotics was determined using Etests and following the breakpoints of the European Committee for Antibiotic Susceptibility Testing (EUCAST)56, except for cefazolin, cefoxitin, cefotetan, tetracycline, doxycycline, and minocycline which were determined using the breakpoints of the Clinical and Laboratory Standards Institute (CLSI)57. The minimum inhibitory concentration of colistin (sulfate, Sigma-Aldrich) was determined by broth microdilution in cation-adjusted Mueller-Hinton broth (Oxoid).

Genome sequencing

Pacific Biosciences (PacBio) RS II Single-Molecule Real Time (SMRT) sequencing of K. pneumoniae MS6671 was performed using ~4 μg of the genomic DNA sheared using g-TUBETM (Covaris®) into fragments size targeted at 10 kb. Purification of the sheared DNA was then carried out using 0.45-fold volume of washed Agencourt AMPure XP magnetic beads (Beckman Coulter Inc.). SMRTbell template libraries were subsequently prepared using the commercial Template Preparation Kit from Pacific Biosciences Inc. that involved steps of DNA end repair, adapters ligation followed by exonuclease digestion of incompletely ligated products. Next, 0.83 nM of the libraries were then annealed with sequencing primers followed by binding to 50 nM of P4 DNA polymerase, as provided in the Template Binding Kit from Pacific Biosciences Inc. For enhanced loading efficiency, 15 pM of the bound complexes were immobilized into Magbeads (Pacific Biosciences Inc.) prior to loading into the sequencing zero-mode waveguides (ZMWs). Duration for the sequence collection was set at 180 minutes with stage start option. Reads with length that were less than 50 bp were filtered off upon acquisition of the sequencing data and minimum polymerase read quality was set at 0.75.

Genome assembly

De novo genome assembly of PacBio SMRT reads from the K. pneumoniae MS6671 genome was performed using the hierarchical genome assembly process (HGAP)58 from the PacBio SMRT analysis software suit (version 2.2.0), with default parameters and a seed read length cut-off of 5 kb. Following assembly, all contigs were screened for duplicate sequences at their 3′ and 5′ ends. Overlapping sequences were manually trimmed and joined based on sequence similarity. Individual contigs with duplicate sequences on their 5′ and 3′ ends were manually trimmed and circularised. Following circularisation the chromosome and plasmid sequences were polished using quiver58 whereby the raw reads were mapped back to the chromosome and plasmid sequences to validate the assembly and resolve any remaining sequence errors. Non-circularised chromosomal and plasmid contigs were closed using primers designed on their 5′ and 3′ ends. The amplified PCR products were sequenced by the Australian Genome Research Facility and their sequences were manually integrated into the assembly.

Genome annotation

Gene calling and automatic functional annotation of the complete MS6671 chromosome and plasmids was performed using Prokka (Prokka: Prokaryotic Genome Annotation System - http://vicbioinformatics.com/) identifying 5,054 putative coding regions on the chromosome with an additional 644 putative coding regions distributed amongst the 5 plasmids and linear plasmid prophage. The complete annotated genome sequence has been deposited at the European Nucleotide Archive (Bioproject: PRJEB7538, Accessions: LN824133-LN824139).

Identification of antibiotic resistance genes

Initial identification of antimicrobial resistance genes from the complete PacBio assembly was performed using ResFinder (version 2.0)59. Additional screening for antimicrobial resistance genes was performed by comparison (BLASTp; sequence identity > =40%; E-value < =0.0001) of all predicted coding regions against the Antibiotic Resistance Genes Database (ARDB)60 and the Comprehensive Antimicrobial Resistance Database (CARD)61. Antimicrobial resistance genes were then subject to manual inspection to improve their functional annotation, correct start sites and identify point mutations, which may contribute to a resistant phenotype. Finally, resistance gene loci were screened for known insertion sequences and integrons by comparison against the ISFinder database62 and Integrall63, respectively.

Additional Information

How to cite this article: Zowawi, H. M. et al. Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae. Sci. Rep. 5, 15082; doi: 10.1038/srep15082 (2015).
  60 in total

Review 1.  The pleiotropic two-component regulatory system PhoP-PhoQ.

Authors:  E A Groisman
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

2.  ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli.

Authors:  Laurent Poirel; Marie-Frédérique Lartigue; Jean-Winoc Decousser; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Antibiotic resistance-the need for global solutions.

Authors:  Ramanan Laxminarayan; Adriano Duse; Chand Wattal; Anita K M Zaidi; Heiman F L Wertheim; Nithima Sumpradit; Erika Vlieghe; Gabriel Levy Hara; Ian M Gould; Herman Goossens; Christina Greko; Anthony D So; Maryam Bigdeli; Göran Tomson; Will Woodhouse; Eva Ombaka; Arturo Quizhpe Peralta; Farah Naz Qamar; Fatima Mir; Sam Kariuki; Zulfiqar A Bhutta; Anthony Coates; Richard Bergstrom; Gerard D Wright; Eric D Brown; Otto Cars
Journal:  Lancet Infect Dis       Date:  2013-11-17       Impact factor: 25.071

4.  Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data.

Authors:  Chen-Shan Chin; David H Alexander; Patrick Marks; Aaron A Klammer; James Drake; Cheryl Heiner; Alicia Clum; Alex Copeland; John Huddleston; Evan E Eichler; Stephen W Turner; Jonas Korlach
Journal:  Nat Methods       Date:  2013-05-05       Impact factor: 28.547

5.  Detection of fosfomycin resistance by the polymerase chain reaction and Western blotting.

Authors:  P García; P Arca; J R Toyos; J E Suárez
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

6.  Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance.

Authors:  Elena López-Camacho; Rosa Gómez-Gil; Raquel Tobes; Marina Manrique; María Lorenzo; Beatriz Galván; Estefanía Salvarelli; Youssef Moatassim; Iñigo J Salanueva; Eduardo Pareja; Francisco M Codoñer; Miguel Alvarez-Tejado; María Pilar Garcillán-Barcia; Fernando De la Cruz; Jesús Mingorance
Journal:  J Antimicrob Chemother       Date:  2013-10-23       Impact factor: 5.790

Review 7.  Hospital-acquired infections due to gram-negative bacteria.

Authors:  Anton Y Peleg; David C Hooper
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

8.  Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers.

Authors:  Hosam M Zowawi; Anna L Sartor; Hanan H Balkhy; Timothy R Walsh; Sameera M Al Johani; Reem Y AlJindan; Mubarak Alfaresi; Emad Ibrahim; Amina Al-Jardani; Seif Al-Abri; Jameela Al Salman; Ali A Dashti; Abdullah H Kutbi; Sanmarié Schlebusch; Hanna E Sidjabat; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

9.  KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December 2011: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units.

Authors:  Sara N Richter; Ilaria Frasson; Elisa Franchin; Cristina Bergo; Enrico Lavezzo; Luisa Barzon; Antonietta Cavallaro; Giorgio Palù
Journal:  Gut Pathog       Date:  2012-07-16       Impact factor: 4.181

10.  ISfinder: the reference centre for bacterial insertion sequences.

Authors:  P Siguier; J Perochon; L Lestrade; J Mahillon; M Chandler
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  44 in total

1.  Impact of the Timing of Antibiotic Administration on Digestive Colonization with Carbapenemase-Producing Enterobacteriaceae in a Murine Model.

Authors:  Rémi Le Guern; Teddy Grandjean; Marvin Bauduin; Martin Figeac; Guillaume Millot; Aurore Loquet; Karine Faure; Eric Kipnis; Rodrigue Dessein
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae Mediated by Chromosomal Integration of Plasmid DNA.

Authors:  Astrid V Cienfuegos-Gallet; Liang Chen; Barry N Kreiswirth; J Natalia Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.

Authors:  William C Shropshire; Samuel L Aitken; Reed Pifer; Jiwoong Kim; Micah M Bhatti; Xiqi Li; Awdhesh Kalia; Jessica Galloway-Peña; Pranoti Sahasrabhojane; Cesar A Arias; David E Greenberg; Blake M Hanson; Samuel A Shelburne
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790

Review 5.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 6.  The Global Ascendency of OXA-48-Type Carbapenemases.

Authors:  Johann D D Pitout; Gisele Peirano; Marleen M Kock; Kathy-Anne Strydom; Yasufumi Matsumura
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

7.  Characterization of Extensively Drug-Resistant or Pandrug-Resistant Sequence Type 147 and 101 OXA-48-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Patients in an Intensive Care Unit.

Authors:  Kalliope Avgoulea; Vincenzo Di Pilato; Olympia Zarkotou; Samanta Sennati; Leda Politi; Antonio Cannatelli; Katerina Themeli-Digalaki; Tommaso Giani; Athanassios Tsakris; Gian Maria Rossolini; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

8.  Emergence and Evolution of Multidrug-Resistant Klebsiella pneumoniae with both blaKPC and blaCTX-M Integrated in the Chromosome.

Authors:  Weihua Huang; Guiqing Wang; Robert Sebra; Jian Zhuge; Changhong Yin; Maria E Aguero-Rosenfeld; Audrey N Schuetz; Nevenka Dimitrova; John T Fallon
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Multihospital Occurrence of Pan-Resistant Klebsiella pneumoniae Sequence Type 147 with an ISEcp1-Directed blaOXA-181 Insertion in the mgrB Gene in the United Arab Emirates.

Authors:  Ágnes Sonnevend; Akela Ghazawi; Rayhan Hashmey; Aliasgher Haidermota; Safinaz Girgis; Mubarak Alfaresi; Mohammed Omar; David L Paterson; Hosam M Zowawi; Tibor Pál
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

10.  Antibiotic pressure on the acquisition and loss of antibiotic resistance genes in Klebsiella pneumoniae.

Authors:  Patricia J Simner; Annukka A R Antar; Stephanie Hao; James Gurtowski; Pranita D Tamma; Clare Rock; Belita N A Opene; Tsigereda Tekle; Karen C Carroll; Michael C Schatz; Winston Timp
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.